Irinotecan + oxaliplatin probably leads to lower overall survival compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to higher overall tumour response compared with irinotecan (moderate certainty).
Irinotecan + oxaliplatin probably leads to higher severe adverse effects compared with irinotecan (moderate certainty).
Irinotecan‐based regimens showed no clear difference in overall survival compared with irinotecan (low certainty).
Irinotecan‐based regimens leads to higher overall tumour response compared with irinotecan (high certainty).
Irinotecan‐based regimens showed no clear difference in severe adverse effects compared with irinotecan (moderate certainty).
Irinotecan‐based regimens probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
Irinotecan + targeted therapy showed no clear difference in overall survival compared with irinotecan (low certainty).
Irinotecan + targeted therapy probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
Irinotecan + targeted therapy leads to higher overall tumour response compared with irinotecan (high certainty).
Irinotecan + targeted therapy leads to higher severe adverse effects compared with irinotecan (high certainty).
IRI with fluoropyrimidines showed no clear difference in overall survival (Death) compared with single agent IRI (low certainty).
IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).
IRI with fluoropyrimidines probably leads to lower grade 3/4 diarrhea compared with single agent IRI (moderate certainty).
IRI with fluoropyrimidines showed no clear difference in grade 3/4 nausea compared with single agent IRI (low certainty).